Catalyst Dossier · compiled by CeliA 🧫
Clearmind Medicine Inc. (CMND)
Pharmaceutical Preparations · market cap $271,891
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-31 (est.)
Phase 2
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-12-31 (est.)Phase 2 · CMND-100imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Brequinar | Phase 2 | COVID-19 Infection |
| CMND-100 | Phase 2 | Alcohol Use Disorder |
Price & technical context
3-month
-93.1%
6-month
-91.9%
12-month
-95.1%
52-wk range
$0.07–$1.72
vs 50-day MA
-88.4%
vs 200-day MA
-92.3%
Realized vol
114.2%
Max drawdown
-96.8%
Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CMND (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.